According to a new report, published by KBV research, The Global Non-invasive Prenatal Testing (NIPT) Market size is expected to reach $17.7 billion by 2030, rising at a market growth of 18.1% CAGR during the forecast period.
The Consumables & Reagents segment is capturing maximum revenue in the Global Non-invasive Prenatal Testing (NIPT) Market by Product in 2022; thereby, achieving a market value of $12.2 billion by 2030. As NIPT gains recognition for its accuracy and safety, more healthcare providers and pregnant individuals opt for this advanced prenatal screening method. This increased adoption directly translates to a higher demand for consumables and reagents necessary for NIPT. The demand for NIPT with greater sensitivity and specificity has led to the development of more precise reagents and consumables.
The Microdeletion Syndrome segment would exhibit a CAGR of 18.4% during (2023 - 2030). Microdeletion Syndromes are a group of genetic disorders characterized by the deletion of a small piece of genetic material from a chromosome. NIPT offers several benefits when applied to the detection of Microdeletion Syndromes, such as 22q11.2 deletion syndrome (DiGeorge syndrome), 1p36 deletion syndrome, and Prader-Willi syndrome. Its non-invasive nature, early and accurate results, reduced anxiety, and ability to provide valuable information for decision-making and improving the health and well-being of both expectant parents and their unborn children.
The Diagnostic Laboratories segment is registering maximum revenue in the Global Non-invasive Prenatal Testing (NIPT) Market by End User in 2022; thereby achieving a market value of $10.6 billion by 2030. One of the primary drivers of the growth of laboratories specializing in NIPT is the increasing demand for non-invasive prenatal testing. As expectant parents and healthcare providers recognize the advantages of NIPT in terms of accuracy and safety, more individuals are opting for these tests. Laboratories are experiencing growth due to the expanding applications of NIPT.
The Next Generation Sequencing (NGS) segment is anticipated to grow at a CAGR of 17.3 % during (2023 – 2030). NGS offers higher accuracy and precision in analyzing fetal DNA than older sequencing technologies. This is crucial for detecting fetal chromosomal abnormalities with greater confidence, reducing false-positive and false-negative results. NGS allows for the analysis of a broader range of genetic information. It can detect various chromosomal abnormalities, including common trisomies (e.g., Trisomy 21, 18, and 13), sex chromosome disorders, and rare genetic conditions and microdeletions.
The North America region is generating the highest revenue in the Global Non-invasive Prenatal Testing (NIPT) Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7.2 billion by 2030. The Europe region is experiencing a CAGR of 17.7% during (2023 - 2030). Additionally, The Asia Pacific region would experience a CAGR of 19.1% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/non-invasive-prenatal-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Illumina, Inc., Natera Inc., F. Hoffmann-La Roche Ltd., PerkinElmer, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific SE, Thermo Fisher Scientific, Inc., GE HealthCare Technologies, Inc., Agilent Technologies, Inc., and Pacific Biosciences of California, Inc.
By Product
By Application
By End User
By Technology
By Geography
Companies Profiled
Unique Offerings 
